On September 26, 2025, Lexaria announced a registered direct offering of 2,666,667 shares of common stock at $1.50 per share, raising $4.0 million in gross proceeds. The offering is priced at‑market under Nasdaq rules and is part of a shelf registration statement effective January 30, 2025. The transaction is expected to close on or about September 29, 2025.
In addition to the share sale, the company issued unregistered warrants to purchase up to 2,666,667 shares at an exercise price of $1.37 per share, exercisable immediately and expiring five years after the resale registration statement becomes effective. The proceeds will be used for working capital and other general corporate purposes. H.C. Wainwright & Co. served as the exclusive placement agent.
This financing event provides Lexaria with additional liquidity to support its drug‑delivery platform development and ongoing clinical programs. The $4.0 million raise is a material capital infusion for a company that has been operating at a net loss and has a “going concern” warning. The at‑market pricing and concurrent warrant issuance reflect the company’s strategy to maintain flexibility while raising capital.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.